false 0001029125 0001029125 2024-06-28 2024-06-28
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
--12-31
FORM 8-K
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
June 28, 2024
Date of Report (Date of Earliest Event Reported)
 
 
Panbela Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
 
 
Delaware
  
001-39468
  
88-2805017
(State of Incorporation)
  
(Commission File Number)
  
(I.R.S. Employer Identification No.)
 
 
712 Vista Blvd #305
Waconia, Minnesota
  
55387
(Address of Principal Executive Offices)
  
(Zip Code)
 
(952) 479-1196
(Registrant’s Telephone Number, Including Area Code)
 
 
(Former Name or Former Address, if Changed Since Last Report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act: None.
 
Securities registered pursuant to Section 12(g) of the Act: Common Stock, $0.001 par value
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 5.03.         Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.
 
Certificate of Elimination
 
As previously reported, Panbela Therapeutics, Inc. (the “Company”) held a special meeting of stockholders on May 28, 2024 at which, among other matters, stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of our outstanding common stock, par value $0.001 per share, at a reverse stock split ratio ranging from any whole number between 1-for-10 and 1-for-45, subject to and as determined by the Board of Directors. Upon the approval by stockholders of the reverse stock split proposal at the special meeting, the sole outstanding share of the Company’s Series A Preferred Stock, par value $0.01 per share, was automatically redeemed. On June 28, 2024, the Company filed a Certificate of Elimination with the Secretary of State of Delaware which, effective upon filing, eliminated all matters set forth in the Certificate of Designation of Series A Preferred Stock filed with the Delaware Secretary of State on April 23, 2024. The foregoing description of the Certificate of Elimination does not purport to be complete and is qualified in its entirety by reference to the Certificate of Elimination, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.
 
Item 9.01         Financial Statements and Exhibits.
 
(d)         Exhibits.
 
Exhibit No.
  
Description
3.1
  
104
  
Cover Page Interactive Data File (the cover page XBRL tags are embedded in the inline XBRL document).
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Panbela Therapeutics, Inc.
  
Date: July 3, 2024
By:
/s/ Susan Horvath
  
   
Susan Horvath
  
   
Chief Financial Officer
  
 
 

Exhibit 3.1

 

PANBELA THERAPEUTICS, INC.

 

CERTIFICATE OF ELIMINATION

OF

SERIES A PREFERRED STOCK

 

Pursuant to the provisions of Section 151(g) of the General Corporation Law of the State of Delaware, it is hereby certified that:

 

FIRST: The name of the corporation (hereinafter referred to as the “Corporation”) is Panbela Therapeutics, Inc. On April 23, 2024, the Corporation filed a Certificate of Designation with respect to its Series A Preferred Stock (defined below), in the office of the Secretary of State of the State of Delaware (the “Series A Certificate of Designation”).

 

SECOND: The issuance of a series of one share of the Corporation’s Series A Preferred Stock, par value $0.001 per share (the “Series A Preferred Stock”), and the rights, preferences, privileges and restrictions of the Series A Preferred Stock were provided for and authorized by resolutions duly adopted by the Board of Directors of the Corporation (the “Board”). A separate certificate setting forth said resolutions has been heretofore filed with the Secretary of State of the State of Delaware pursuant to the provisions of Section 151(g) of the General Corporation Law of the State of Delaware.

 

THIRD: No shares of said Series A Preferred Stock are outstanding and no shares thereof will be issued subject to said Series A Certificate of Designation.

 

FOURTH: The Board has adopted the following resolutions:

 

WHEREAS, the Corporation has no authorized share of Series A Preferred Stock outstanding, and no authorized share of Series A Preferred Stock will be issued.

 

RESOLVED, that the officers of the Corporation are each hereby authorized, jointly and severally, for and on behalf of the Corporation, to execute and file a certificate setting forth this resolution (a “Certificate of Elimination”) with the Secretary of State of the State of Delaware pursuant to the provisions of Section 151(g) of the General Corporation Law of the State of Delaware for the purpose of eliminating from the Certificate of Incorporation of the Corporation all reference to the Series A Preferred Stock of the Corporation.

 

FIFTH: The effective time of this Certificate of Elimination shall be upon filing with the Secretary of State of the State of Delaware.

 

 

[Remainder of Page Intentionally Left Blank]
 

 
 

 

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Elimination to be duly executed by the undersigned duly authorized officer as of this 28th day of June, 2024.

 

     

PANBELA THERAPEUTICS, INC.
   

By:

  

/s/ Jennifer K. Simpson
   

Name: Jennifer K. Simpson
   

Title: President and Chief Executive Officer

 

 
v3.24.2
Document And Entity Information
Jun. 28, 2024
Document Information [Line Items]  
Entity, Registrant Name Panbela Therapeutics, Inc.
Current Fiscal Year End Date --12-31
Document, Type 8-K
Document, Period End Date Jun. 28, 2024
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-39468
Entity, Tax Identification Number 88-2805017
Entity, Address, Address Line One 712 Vista Blvd #305
Entity, Address, City or Town Waconia
Entity, Address, State or Province MN
Entity, Address, Postal Zip Code 55387
City Area Code 952
Local Phone Number 479-1196
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0001029125
Panbela Therapeutics (NASDAQ:PBLA)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025 Click aqui para mais gráficos Panbela Therapeutics.
Panbela Therapeutics (NASDAQ:PBLA)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025 Click aqui para mais gráficos Panbela Therapeutics.